Is Cytiva profitable and how is it doing in 2026?

Cytiva doesn't report standalone profit; it sits inside Danaher's Biotechnology segment. Danaher posted FY2025 sales of $24.6B with 2% core growth, and Q1 2026 bioprocessing equipment orders surged over 30% YoY, the first positive growth in nearly two years, as of July 20, 2026.

Cytiva is wholly owned by Danaher Corporation (NYSE: DHR), a US conglomerate. Cytiva launched April 1, 2020 after Danaher completed a $21.4B acquisition of GE Healthcare's Biopharma business, and merged with Pall Corporation in May 2023 to form Danaher's Biotechnology Group.

Is Cytiva laying people off?

Yes, Cytiva laid off 85 employees at its Westborough, MA facility effective March 7, 2025, per a WARN notice filed December 18, 2024. Headcount has drifted from over 16,000 in 2023 to about 15,000 by an April 2026 press release, even as it adds jobs at other sites.

Could AI replace Cytiva's core business?

Unlikely in the near term. Cytiva's moat is physical, regulatory-locked hardware and consumables like chromatography resins used in FDA-approved biologic manufacturing, which biopharma rarely re-qualifies once validated. AI mainly touches thinner data-analysis and SCADA layers, such as its 2026 Figurate platform with Rockwell Automation.

Who is Cytiva's biggest competitor?

Sartorius AG is the most cited direct rival, taking share in filtration and single-use bioprocessing and launching an AI-based Bioprocess Digital Twin platform in June 2025. Cytiva reportedly still holds around 80% of chromatography resin share per one industry-expert estimate from June 2026, though this is not audited data.

Is Cytiva a safe company to join in 2026?

Mixed signals: Cytiva cut 85 jobs at Westborough, MA in March 2025 amid sector-wide biopharma restructuring, but simultaneously invested $1.6B in manufacturing capacity through 2028 and added roles in Muskegon, MI and Logan, UT. Site-level stability varies more than company-wide trend.

Biotech tools companies · subsidiary of Danaher Corporation · Sweden

Cytiva

cytiva.com ↗

Danaher-owned maker of chromatography resins and bioprocessing gear for biologic drug makers.

Hard to displace

Assessed 24 July 2026 · Evidence as of 24 July 2026

Strong structural protection; the business model survives ai pressure.

On the recordSince 24 July 2026 · Checkable from around July 21, 2026 · Every call on the record Checkpoint: Danaher Q2 2026 earnings report, testing whether the Q1 order surge holds

The call

Cytiva keeps its grip on the resins already built into approved drugs, even as Sartorius chips away at the newer filtration and single-use side of the business.

Cytiva makes chromatography resins and filtration products that drug manufacturers use to purify biologics like insulin and antibodies. Once a drug maker gets FDA approval using Cytiva's resins, switching to a rival like Purolite or Sartorius would require re-qualifying the entire drug, which regulators rarely allow, so customers stay locked in even if competitors offer lower prices. The main risk is whether Sartorius can steal market share in newer single-use filtration systems (where switching is easier) or whether their new AI analytics tools become so good that they pull customers away from the resin business too, though the physical and regulatory lock-in makes this unlikely. Watch Q2 2026 earnings in July to see if the recent jump in equipment orders holds up, and whether the company's recent layoffs in Massachusetts signal trouble ahead.

Why

AI pressure: None apparent. AI analytics tools can optimize workflows but cannot replace FDA-qualified resins already locked into approved drug processes. Could AI do the core job? Unlikely.

Bigger players: Sartorius AG. Sartorius is winning share in filtration and single-use consumables, the fastest-growing edge of bioprocessing, while Cytiva's core resin base holds. Could a giant copy it? No, they are blocked.

What protects it. Once a resin is qualified inside an approved biologic manufacturing process, swapping suppliers requires costly FDA re-validation, locking customers in.

What would change this call

Sartorius reports filtration/single-use revenue growth outpacing Cytiva/Pall in 2026 earnings. Would confirm Sartorius is durably taking bioprocessing share beyond resin edges.
Danaher's Q2 2026 earnings (~Jul 21, 2026) show whether Q1's 30% order surge sustained or reversed. Tests if bioprocessing demand recovery is real or a one-quarter blip.
A biologic drug gains FDA approval using a non-Cytiva chromatography resin platform. Would signal cracks in Cytiva's qualification lock-in moat.

Key numbers

Bioprocessing equipment orders up over 30% YoY (Q1 2026)
Danaher parent FY2025 revenue $24.6B, 2% core growth (2026-01-28)
$1.6B invested in manufacturing capacity since 2019 (2026-07-23)

Named risks

Sartorius or new entrants erode chromatography resin qualification lock-in on newly approved biologics. Severity: medium
Sustained pharma capex freeze beyond 18 months could stall bioprocessing equipment recovery. Severity: medium
Tariff-related cost pressures and MFN drug-pricing negotiations affecting customer capex decisions. Severity: medium
Site-level layoffs (e.g., Westborough MA, 85 jobs March 2025) signal uneven headcount stability despite overall growth. Severity: low
Continued share loss in filtration/single-use to Sartorius could widen into adjacent product lines. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Sartorius AG	gaining on	Taking share in filtration/single-use bioprocessing; launched AI Bioprocess Digital Twin platform June 2025
Purolite	contesting	Price competition in chromatography resin market noted by industry expert, June 2026
Thermo Fisher Scientific	contesting	Broad competitor across life-science tools and single-use bioprocessing with large manufacturing scale
Merck KGaA/MilliporeSigma	contesting	Named peer competitor in bioprocessing tools and consumables market
Repligen Corporation	contesting	Named peer in bioprocessing filtration and consumables space

Questions people ask

Is Cytiva profitable and how is it doing in 2026?: Cytiva doesn't report standalone profit; it sits inside Danaher's Biotechnology segment. Danaher posted FY2025 sales of $24.6B with 2% core growth, and Q1 2026 bioprocessing equipment orders surged over 30% YoY, the first positive growth in nearly two years, as of July 20, 2026.
Who owns Cytiva?: Cytiva is wholly owned by Danaher Corporation (NYSE: DHR), a US conglomerate. Cytiva launched April 1, 2020 after Danaher completed a $21.4B acquisition of GE Healthcare's Biopharma business, and merged with Pall Corporation in May 2023 to form Danaher's Biotechnology Group.
Is Cytiva laying people off?: Yes, Cytiva laid off 85 employees at its Westborough, MA facility effective March 7, 2025, per a WARN notice filed December 18, 2024. Headcount has drifted from over 16,000 in 2023 to about 15,000 by an April 2026 press release, even as it adds jobs at other sites.
Could AI replace Cytiva's core business?: Unlikely in the near term. Cytiva's moat is physical, regulatory-locked hardware and consumables like chromatography resins used in FDA-approved biologic manufacturing, which biopharma rarely re-qualifies once validated. AI mainly touches thinner data-analysis and SCADA layers, such as its 2026 Figurate platform with Rockwell Automation.
Who is Cytiva's biggest competitor?: Sartorius AG is the most cited direct rival, taking share in filtration and single-use bioprocessing and launching an AI-based Bioprocess Digital Twin platform in June 2025. Cytiva reportedly still holds around 80% of chromatography resin share per one industry-expert estimate from June 2026, though this is not audited data.
Is Cytiva a safe company to join in 2026?: Mixed signals: Cytiva cut 85 jobs at Westborough, MA in March 2025 amid sector-wide biopharma restructuring, but simultaneously invested $1.6B in manufacturing capacity through 2028 and added roles in Muskegon, MI and Logan, UT. Site-level stability varies more than company-wide trend.

Timeline

2026-07-23Cytiva reports completion of $1.6B multi-year manufacturing capacity expansion across US, Europe, Asia
2026-07-20Analysts flag Q1 2026 bioprocessing equipment orders up over 30% YoY, first growth in ~2 years
2026-07-16Cytiva renews 30-year supply partnership with GC Biopharma for biologics consumables
2026-06Cytiva completes doubling of Utah site's liquid media production capacity
2026-04-29Cytiva and Rockwell Automation launch Figurate SCADA digital manufacturing platform
2026-01-28Danaher reports FY2025 sales of $24.6B, guides Biotechnology segment as fastest-growing into 2026
2025-09-25Cytiva launches new flagship Protein A resins for clinical and commercial manufacturing
2025-03-07Cytiva lays off 85 employees at Westborough, MA facility
2023-05Cytiva merges with Pall Corporation, forming Danaher's Biotechnology Group with 16,000+ associates
2020-04-01Cytiva brand launches after Danaher's $21.4B acquisition of GE Healthcare Biopharma closes

Revision history

24 July 2026

First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.

In the same band

Merck KGaA (MilliporeSigma)Intertek Group plc Eurofins Scientific SE